Low-Dose Insulin Lispro Sliding Scale Protocol
Sliding scale insulin alone (correction-only insulin) should NOT be used as monotherapy in hospitalized patients with diabetes, except in non-diabetic patients with mild stress hyperglycemia. 1, 2
Why Sliding Scale Alone is Inadequate
The evidence is clear and consistent: sliding scale insulin (SSI) as sole therapy results in poor glycemic control, treats hyperglycemia only after it occurs rather than preventing it, and has been condemned in clinical guidelines for over a decade 1, 2, 3. For patients with established diabetes (Type 1 or Type 2), you must use a basal-bolus regimen with correction doses, not sliding scale alone 1.
Recommended Low-Dose Protocol: Basal-Plus Approach
For patients requiring low-dose insulin (those at high risk for hypoglycemia or with mild hyperglycemia), use a basal-plus regimen 1:
Initial Dosing Algorithm
Step 1: Calculate Total Daily Dose (TDD)
- Low-dose patients: 0.1-0.25 units/kg/day for basal insulin only 1
- Use the lower end (0.1 units/kg) for:
Step 2: Administer Basal Insulin
- Give entire calculated dose as once-daily long-acting insulin (glargine, detemir, or degludec)
Step 3: Add Correction Doses of Insulin Lispro
- Give rapid-acting insulin lispro only for correction before meals or every 6 hours if NPO
- Use correction doses when blood glucose exceeds target thresholds
Correction Dose Scale for Insulin Lispro
For insulin-sensitive patients (low-dose protocol):
| Blood Glucose | Correction Dose |
|---|---|
| 141-180 mg/dL | 1-2 units |
| 181-220 mg/dL | 2-3 units |
| 221-260 mg/dL | 3-4 units |
| 261-300 mg/dL | 4-5 units |
| >300 mg/dL | 5-6 units and notify physician |
Hold correction dose if blood glucose <140 mg/dL 1
When Sliding Scale Alone IS Appropriate
The only acceptable use of sliding scale insulin lispro alone is in 1:
- Non-diabetic patients with mild stress hyperglycemia
- Patients without diabetes who develop glucose >180 mg/dL during hospitalization
- Patients with well-controlled diabetes (on oral agents at home) who cannot maintain glucose <180 mg/dL in hospital
Critical Pitfalls to Avoid
Never use sliding scale alone in Type 1 diabetes - this is dangerous and can lead to DKA 1
Don't use aggressive correction for moderate hyperglycemia - Recent evidence shows that correcting only when glucose >260 mg/dL (rather than >140 mg/dL) in patients on adequate basal-bolus regimens produces equivalent glycemic control with less hypoglycemia 5
Renal and hepatic impairment require dose reduction - These patients have decreased insulin clearance and are at significantly higher risk for hypoglycemia 4
Monitor for hypoglycemia risk - Basal-bolus regimens carry 4-6 times higher hypoglycemia risk than sliding scale alone, though they provide superior glycemic control 1
Transition to Full Basal-Bolus if Needed
If the basal-plus approach fails to maintain glucose <180 mg/dL, escalate to full basal-bolus 1:
- TDD: 0.3-0.5 units/kg/day
- 50% as basal insulin (once or twice daily)
- 50% as prandial insulin lispro (divided before 3 meals)
- Continue correction doses as above
Evidence Quality Note
The 2024 ADA Standards 2 and 2021 Lancet guidelines 1 provide the strongest, most recent evidence explicitly discouraging sliding scale monotherapy. The Cochrane review 6 confirms very low-certainty evidence for SSI effectiveness, with basal-bolus showing better glycemic control despite higher hypoglycemia risk.